Related Experiment Video
Updated: May 21, 2026

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
P53 mdm2 inhibitors
1University of Pittsburgh, Department of Pharmaceutical Sciences, Pittsburgh, PA 15261, USA.
Abstract:
The protein-protein interaction (PPI) between p53 and its negative regulator MDM2 comprises one of the most important and intensely studied PPI's involved in preventing the initiation of cancer. The interaction between p53 and MDM2 is conformation-based and is tightly regulated on multiple levels. Due to the Angstrom level structural insight there is a reasonable understanding of the structural requirements needed for a molecule to bind to MDM2 and successfully inhibit the p53/MDM2 interaction. The current review summarizes the binding characteristics of the different disclosed small molecules for inhibition of MDM2 with a co-crystal structure. Synthetic access to these compounds as well as their derivatives are described in detail.
Insights
Small molecules inhibiting the p53-MDM2 interaction are crucial for cancer prevention. This review details small molecules that bind MDM2, offering structural insights and synthetic routes for potential cancer therapies.
Area of Science:
- Biochemistry
- Molecular Biology
- Medicinal Chemistry
Background:
- The p53-MDM2 protein-protein interaction (PPI) is a critical regulator in cancer prevention.
- This interaction is conformation-based and tightly regulated.
- Understanding structural requirements for MDM2 inhibitors is key to developing cancer therapies.
Purpose of the Study:
- To review small molecules that inhibit the p53-MDM2 interaction.
- To summarize binding characteristics of disclosed inhibitors with co-crystal structures.
- To detail synthetic access and derivatives of these inhibitory compounds.
Main Methods:
- Structural analysis of MDM2-inhibitor complexes.
- Review of published co-crystal structures.
- Summary of synthetic chemistry approaches.
Main Results:
- Detailed characterization of small molecules binding to MDM2.
- Provided Angstrom-level structural insights into inhibitor binding.
- Described synthetic pathways for disclosed inhibitors and their analogs.
Conclusions:
- Small molecule inhibitors targeting the p53-MDM2 interaction are viable for cancer therapy development.
- Co-crystal structures provide valuable information for rational drug design.
- Synthetic accessibility of these inhibitors facilitates further research and development.
Related Concept Videos
Abnormal Proliferation
Negative Regulator Molecules
Inhibition of Cdk Activity
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

